Cara Therapeutics, Inc. (0HTC.L)

USD 5.33

(-0.22%)

Operating Income Summary of Cara Therapeutics, Inc.

  • Cara Therapeutics, Inc.'s latest annual operating income in 2023 was -121.49 Million USD , down -38.8% from previous year.
  • Cara Therapeutics, Inc.'s latest quarterly operating income in 2024 Q2 was -16.21 Million USD , up 40.53% from previous quarter.
  • Cara Therapeutics, Inc. reported an annual operating income of -87.53 Million USD in 2022, up 1.74% from previous year.
  • Cara Therapeutics, Inc. reported an annual operating income of -89.08 Million USD in 2021, down -1754.28% from previous year.
  • Cara Therapeutics, Inc. reported a quarterly operating income of -27.26 Million USD for 2024 Q1, up 16.38% from previous quarter.
  • Cara Therapeutics, Inc. reported a quarterly operating income of -28.03 Million USD for 2023 Q3, up 13.32% from previous quarter.

Annual Operating Income Chart of Cara Therapeutics, Inc. (2023 - 2011)

Historical Annual Operating Income of Cara Therapeutics, Inc. (2023 - 2011)

Year Operating Income Operating Income Growth
2023 -121.49 Million USD -38.8%
2022 -87.53 Million USD 1.74%
2021 -89.08 Million USD -1754.28%
2020 5.38 Million USD 104.82%
2019 -111.67 Million USD -44.32%
2018 -77.38 Million USD -30.09%
2017 -59.48 Million USD -1.86%
2016 -58.4 Million USD -131.86%
2015 -25.18 Million USD -39.38%
2014 -18.07 Million USD -7525.32%
2013 -237 Thousand USD 96.2%
2012 -6.23 Million USD 34.81%
2011 -9.56 Million USD 0.0%

Peer Operating Income Comparison of Cara Therapeutics, Inc.

Name Operating Income Operating Income Difference
Editas Medicine, Inc. -169.18 Million USD 28.186%
Dynavax Technologies Corporation -37.02 Million USD -228.117%
Walgreens Boots Alliance, Inc. -14.07 Billion USD 99.137%
Supernus Pharmaceuticals, Inc. -5.26 Million USD -2205.846%
Perrigo Company plc 151.9 Million USD 179.984%
Atara Biotherapeutics, Inc. -276 Million USD 55.981%
Illumina, Inc. -1.06 Billion USD 88.635%
Thermo Fisher Scientific Inc. 6.85 Billion USD 101.771%
Nektar Therapeutics -137.42 Million USD 11.592%
Iovance Biotherapeutics, Inc. -460.55 Million USD 73.62%
IQVIA Holdings Inc. 1.97 Billion USD 106.145%
Heron Therapeutics, Inc. -110.61 Million USD -9.836%
Unity Biotechnology, Inc. -44.66 Million USD -172.002%
BioMarin Pharmaceutical Inc. 194.44 Million USD 162.484%
Waters Corporation 817.67 Million USD 114.859%
Biogen Inc. 1.29 Billion USD 109.369%
Sangamo Therapeutics, Inc. -274 Million USD 55.66%
Adicet Bio, Inc. -152.03 Million USD 20.089%
Evolus, Inc. -49.23 Million USD -146.776%
bluebird bio, Inc. -244.26 Million USD 50.26%
Aclaris Therapeutics, Inc. -97.35 Million USD -24.793%
Esperion Therapeutics, Inc. -155.56 Million USD 21.9%
FibroGen, Inc. -281.81 Million USD 56.888%
Agilent Technologies, Inc. 1.35 Billion USD 109.0%
Homology Medicines, Inc. -48.25 Million USD -151.777%
Geron Corporation -193.94 Million USD 37.356%
Alnylam Pharmaceuticals, Inc. -282.17 Million USD 56.943%
Corbus Pharmaceuticals Holdings, Inc. -45.07 Million USD -169.526%
Amicus Therapeutics, Inc. -73.49 Million USD -65.313%
Myriad Genetics, Inc. -123.7 Million USD 1.783%
Regeneron Pharmaceuticals, Inc. 4.04 Billion USD 103.002%
OPKO Health, Inc. -157.02 Million USD 22.625%
Viking Therapeutics, Inc. -100.82 Million USD -20.498%
Intellia Therapeutics, Inc. -515.29 Million USD 76.422%
Zoetis Inc. 3.06 Billion USD 103.959%
Abeona Therapeutics Inc. -48.2 Million USD -152.064%
Mettler-Toledo International Inc. 1.08 Billion USD 111.174%
Exelixis, Inc. 170.88 Million USD 171.098%
Vertex Pharmaceuticals Incorporated 4.3 Billion USD 102.821%
uniQure N.V. -282.87 Million USD 57.049%
Kala Pharmaceuticals, Inc. -39.15 Million USD -210.308%
Anavex Life Sciences Corp. -55.75 Million USD -117.905%
Axsome Therapeutics, Inc. -231.82 Million USD 47.592%
Verastem, Inc. -92.08 Million USD -31.939%
Imunon, Inc. -21.03 Million USD -477.71%
Ionis Pharmaceuticals, Inc. -353.73 Million USD 65.653%
Sarepta Therapeutics, Inc. -267.82 Million USD 54.636%
Neurocrine Biosciences, Inc. 250.9 Million USD 148.424%
Corcept Therapeutics Incorporated 107.28 Million USD 213.248%
Halozyme Therapeutics, Inc. 337.57 Million USD 135.991%
TG Therapeutics, Inc. 20.63 Million USD 688.838%
Blueprint Medicines Corporation -486.27 Million USD 75.015%
Insmed Incorporated -709.62 Million USD 82.879%
Agios Pharmaceuticals, Inc. -391.48 Million USD 68.966%
Incyte Corporation 620.52 Million USD 119.579%
Emergent BioSolutions Inc. -726.4 Million USD 83.274%